Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors.
Eric T RobertsGabriela SchmajukJing LiMatthew MurrillRebecca GraingerPublished in: Arthritis care & research (2024)
We report higher screening rates than have previously been published because of combining claims and EHR data. However, important safety gaps remain, namely, reduced screening among new users of a JAKi or IL-17i and among Asian and Hispanic patients, as well as low-performing practices. Educational initiatives, team-based care delivery, task shifting, and technological interventions to address observed gaps in patient safety procedures are needed.
Keyphrases
- patient safety
- quality improvement
- healthcare
- rheumatoid arthritis
- palliative care
- primary care
- end stage renal disease
- ejection fraction
- electronic health record
- newly diagnosed
- randomized controlled trial
- systematic review
- prognostic factors
- deep learning
- machine learning
- health insurance
- cancer therapy
- emergency department
- drug delivery
- rheumatoid arthritis patients
- chronic pain
- human immunodeficiency virus
- disease activity
- meta analyses